Last updated: 2026-09-16 12:42:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.95, with a market capitalisation of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.61 to $1.40. This page covers its latest market performance, valuation, price trends and company information.
-- | |
$0.95 | |
$1.40 | |
$0.61 | |
$0.95 | |
-- | |
10.30K | |
-- | |
$1.40 | |
$0.61 | |
-- | |
-- |
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is trading at $0.95 in pre-market trading as of 2026-09-16 12:30:00, unchanged from the previous close of $0.95
Pre-market trading shows how investors are pricing BCTXL before the regular session opens. The current pre-market price is near the previous close, indicating neutral early trading sentiment.
Over the past seven days, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) moved from $0.95 to $0.95, representing a gain of 0.36% ($0.00).
The stock traded between $0.83 and $0.99 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 15.14 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 43.0%
BCTXL is currently trading at $0.95, placing it 43.0% of the way from its 52-week low of $0.61 to its 52-week high of $1.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.